$IMCR News

Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet

A Look At Immunocore (IMCR) Valuation After Strong Q1 2026 Results And New KIMMTRAK Survival Data

Immunocore (IMCR) Is Up 10.1% After Q1 Profitability Jumps On Higher Revenue And Efficiency

Immunocore reports first quarter financial results and provides a business update

Immunocore Hldgs Q1 EPS $0.25 Beats $(0.25) Estimate, Sales $106.677M Miss $107.731M Estimate

HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target

Reported Sunday, KIMMTRAK Five-Year Phase 3 Data Shows Doubled Survival Likelihood Versus Investigator's Choice With Median OS Of 21.6 Months Versus 16.9 Months In Metastatic Uveal Melanoma

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target

Immunocore Details KIMMTRAK Growth, TCR Platform and Key Readouts at Needham Conference

Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference

A Look At Immunocore (IMCR) Valuation After Jefferies Downgrade And Kimmtrak Growth Concerns

Jefferies Downgrades Immunocore Holdings plc (IMCR) to Hold with a $33 Price Target

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Immunocore Holdings To Present 5-Yr OS From KIMMTRAK Phase 3 Trial In Previously Untreated HLA-A*02:01 Positive Patients With Unresected Or mUM, At 2026 AACR Annual Meeting

Jefferies Downgrades Immunocore Holdings to Hold, Lowers Price Target to $33

Immunocore to present at upcoming investor conferences

Is It Time To Revisit Immunocore Holdings (IMCR) After Recent Pipeline Progress?

Needham Maintains Buy on Immunocore Holdings, Raises Price Target to $75

Immunocore Holdings plc 2025 Q4 - Results - Earnings Call Presentation